文献速递前列腺增生与排尿功能障碍

种族和社会经济因素影响商业保险OAB患者接受先进疗法的使用

Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients.
PubMed 文献 · Urology · 2020-05-19

该研究基于Optum全国索赔数据库2003–2017年数据,纳入4,229,617例非神经源性OAB患者,其中807,612例(19%)接受药物治疗,仅4.7%接受先进疗法;亚洲人使用口服药物和先进疗法的比例最低,女性、年轻、高收入及既往口服药物使用与接受先进疗法显著相关,非白人种族、低教育水平及东北地区与较低可能性相关。

要点

  • 商业保险OAB患者中仅19%接受药物治疗,其中95%仅用口服药,4.7%用先进疗法。
  • 亚洲人使用口服药(14% vs 18%-19%)和先进疗法(0.44% vs 0.71%-0.93%)比例最低。
  • 女性、<65岁、年收入≥4万美元、既往口服药使用与接受先进疗法显著相关。

核心结论

  • 在商业保险OAB患者中,种族/民族、年龄、性别、教育水平和地区可预测先进疗法的使用。

研究设计与样本

  • 基于Optum全国索赔数据库2003–2017年的回顾性分析,纳入4,229,617例非神经源性OAB患者。

主要发现

  • 807,612例(19%)接受药物治疗,其中95%仅用口服药,4.7%接受先进疗法。
  • 亚洲人口服药物使用率14%(其他种族18%-19%,P<0.05),先进疗法使用率0.44%(其他种族0.71%-0.93%,P<0.05)。
  • 亚洲人和西班牙裔最不可能使用SNS,最可能使用PTNS。
  • BTX使用率在种族/民族间相似(P<0.05)。

关键数值与推荐

  • 女性(OR 1.65 [CI 1.61,1.69])、年龄<65岁(OR 1.28 [1.25,1.31])、年收入≥4万美元(OR 1.09 [1.06,1.12])、既往使用1种口服药(OR 3.30 [3.21,3.38])与接受先进疗法显著相关。
  • 非白人种族(OR 0.89 [0.87,0.91])、教育水平低于学士学位(OR 0.97 [0.94,0.99])及东北地区与较低可能性相关(P<0.05)。

临床怎么用

  • 临床中应关注OAB先进疗法使用中的种族和社会经济差异,确保公平可及。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if racial and/or socioeconomic factors influence advanced therapy utilization for refractory overactive bladder (OAB) among the commercially insured. METHODS: We queried Optum, a national claims database, between 2003 and 2017. Non-neurogenic OAB patients were identified using ICD-9/10 diagnosis codes. Demographic and treatment data were collected, including oral medication therapies (anticholinergic, beta3 agonists), and advanced therapies (OnabotulinumtoxinA [BTX], Sacral Nerve Stimulation [SNS], percutaneous tibial nerve stimulation [PTNS]). Associations between patient sociodemographic factors and advanced therapy utilization were explored. RESULTS: Of 4,229,617 OAB patients, 807,612 (19%) received medical therapies, of which 95% received oral medications only and only 4.7% received advanced therapies. Asians had the lowest use of oral therapy use (14% vs 18%-19% in other races/ethnicities, P <0.05), and advanced therapy use (0.44% vs 0.71%-0.93%, P <0.05). Asians and Hispanics were least likely to utilize SNS therapy and most likely to use PTNS compared to Blacks and Whites. BTX use was similar between races/ethnicities (P <0.05). Female gender (OR 1.65 [CI 1.61,1.69]), younger age (<65) (OR 1.28 [1.25,1.31]), higher annual income ≥$40K (OR 1.09 [1.06,1.12]) and prior use of oral medications (OR 3.30 [3.21,3.38] for 1 medication) were significantly associated with receiving advanced therapies. Non-white race (OR 0.89 [0.87,0.91]), lower education level (less than a bachelor's degree) (OR 0.97 [0.94,0.99]), and Northeast region were associated with a lower likelihood of receiving advanced therapies (P <0.05 for all). CONCLUSION: Among commercially insured, racial and socioeconomic factors predict utilization of advanced OAB therapies, including race/ethnicity, age, gender, education level, and region.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Syan R, Zhang CA, Enemchukwu EA, et al. Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients. Urology. 2020. PMID: 32439551. doi:10.1016/j.urology.2020.04.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。